Article Text

Download PDFPDF
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
  1. Shomron Ben-Horin
  1. Correspondence to Dr Shomron Ben-Horin, Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52621, Israel; sben-horin{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I read with interest the study by Leiper and colleagues,1 and the authors should be commended for initiating this investigator-driven study. However, I beg to differ with the conclusion that reads ‘Rituximab has no significant effect on inducing remission in moderately active UC [ulcerative colitis] not responding to oral steroids.’

The authors state that the sample-size calculations were based on 80% power for excluding, at p<0.05, an 80% remission rate with active treatment compared with a predicted 25% placebo remission rate …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.